|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1089126304 |
| 003 |
OCoLC |
| 005 |
20231120010343.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190304s2019 ne a ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d YDX
|d OPELS
|d EBLCP
|d UAB
|d UKMGB
|d MERER
|d NRC
|d UKAHL
|d OCLCF
|d STF
|d ESU
|d DCT
|d OCLCQ
|d ERF
|d OCLCQ
|d S2H
|d OCLCO
|d LVT
|d VT2
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d COM
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 015 |
|
|
|a GBB930435
|2 bnb
|
| 015 |
|
|
|a GBB928959
|2 bnb
|
| 016 |
7 |
|
|a 019252564
|2 Uk
|
| 019 |
|
|
|a 1089201158
|a 1229491360
|a 1244447289
|a 1249235879
|
| 020 |
|
|
|a 9780128144718
|q (electronic bk.)
|
| 020 |
|
|
|a 0128144718
|q (electronic bk.)
|
| 020 |
|
|
|z 012814470X
|
| 020 |
|
|
|z 9780128144701
|
| 035 |
|
|
|a (OCoLC)1089126304
|z (OCoLC)1089201158
|z (OCoLC)1229491360
|z (OCoLC)1244447289
|z (OCoLC)1249235879
|
| 050 |
|
4 |
|a QP620
|
| 060 |
|
4 |
|a QV 185
|
| 072 |
|
7 |
|a MED
|x 005000
|2 bisacsh
|
| 072 |
|
7 |
|a SCI
|x 036000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 611.01816
|2 23
|
| 245 |
0 |
0 |
|a Nucleic acid nanotheranostics :
|b biomedical applications /
|c edited by Marco Filice, Jes�us Ruiz-Cabello.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c [2019]
|
| 264 |
|
4 |
|c �2019
|
| 300 |
|
|
|a 1 online resource :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Micro & nano technologies series
|
| 588 |
0 |
|
|a Print version record.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Front Cover; Nucleic Acid Nanotheranostics: Biomedical Applications; Copyright; Dedication; Contents; Contributors; Preface; Acknowledgments; Chapter 1: Therapeutic Oligonucleotides Against Cancer: Recent Approaches and New Perspectives; 1. Introduction; 2. Mechanisms of Action; 2.1. Antisense Oligodeoxynucleotides (AS-ODNs); 2.2. Small Inhibitory RNAs (siRNAs) and microRNAs (miRNAs); 2.3. Immunostimulatory ODNs (IMOs); 2.4. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 2.5. Aptamers; 3. Delivery; 3.1. Physiological Barriers for TONs Activity; 3.2. Delivery of Naked TONs
|
| 505 |
8 |
|
|a 3.3. Conjugated TONs3.4. Delivery of Encapsulated TONs; 3.4.1. Lipidic Carriers; 3.4.2. Nonlipidic Bionanoparticles; 3.4.3. Polymeric Carriers; 4. Therapeutic Antisense Oligodeoxynucleotides (AS-ODNs) in Cancer; 5. Small Interfering RNA (siRNA); 6. MicroRNA (miRNA); 7. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 8. Aptamers; 9. Conclusions; References; Chapter 2: Small Interfering RNA-Mediated Silencing of the Ribophorin II Gene: Advances in the Treatment of Malignant Bre ... ; 1. Introduction; 2. Biology of RPN2; 2.1. Regulation of Chemoresistance; 2.1.1. Breast Cancer
|
| 505 |
8 |
|
|a 3.2. Toxicity test for RPN2-siRNA4. Conclusion; Acknowledgments; References; Chapter 3: Noncoding RNAs in Cardiovascular Disease; 1. Introduction; 2. Micro-RNAs; 2.1. Biogenesis; 2.2. Mechanism of Action; 3. Long Noncoding RNAs; 3.1. Biogenesis; 3.2. Mechanisms of Action; 3.3. Nuclear lncRNA; 3.3.1. Lnc-RNA-Mediated Methylation; 3.3.2. Direct Heterochromatin Formation; 3.3.3. Transcriptional Interference; 3.3.4. Decoy; 3.3.5. Polymerase II Inhibitors; 3.3.6. Transcriptional Coregulators; 3.3.7. Paraspeckles; 3.3.8. Splicing Modulation; 3.4. Cytoplasmic lncRNAs
|
| 505 |
8 |
|
|a 3.4.1. mRNA Stability Modulation3.4.2. Translational Regulation; 3.4.3. miRNA-lncRNA Interaction; 4. Role of miRNA and lncRNA in Cardiovascular Development and Disease; 4.1. miRNA in Cardiovascular Development; 4.2. miRNA in Cardiovascular Disease; 4.2.1. Fibrosis; 4.2.2. Cardiomyocyte Hypertrophy; 4.2.3. Myocardial Infarction; 4.2.4. Myosin Switching; 4.3. lncRNA in Cardiovascular Development; 4.4. lncRNA in Cardiovascular Disease; 5. ncRNA Therapeutics; 5.1. siRNA and miRNA Therapeutics; 5.1.1. Chemical Modifications to Increase Stability; 5.1.1.1. Backbone Modifications
|
| 650 |
|
0 |
|a Nucleic acids.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Biomedical materials.
|
| 650 |
1 |
2 |
|a Nucleic Acids
|x therapeutic use
|0 (DNLM)D009696Q000627
|
| 650 |
1 |
2 |
|a Drug Carriers
|x therapeutic use
|0 (DNLM)D004337Q000627
|
| 650 |
2 |
2 |
|a Theranostic Nanomedicine
|x methods
|0 (DNLM)D000068936Q000379
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
4 |
|a MEDICAL
|x Anatomy.
|
| 650 |
|
4 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|
| 650 |
|
6 |
|a Biomat�eriaux.
|0 (CaQQLa)201-0025723
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
7 |
|a MEDICAL
|x Anatomy.
|2 bisacsh
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|2 bisacsh
|
| 650 |
|
7 |
|a Biomedical materials
|2 fast
|0 (OCoLC)fst00832586
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 650 |
|
7 |
|a Nucleic acids
|2 fast
|0 (OCoLC)fst01041070
|
| 700 |
1 |
|
|a Filice, Marco,
|e editor.
|
| 700 |
1 |
|
|a Ruiz-Cabello, Jes�us,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t NUCLEIC ACID NANOTHERANOSTICS.
|d [Place of publication not identified], ELSEVIER, 2019
|z 012814470X
|w (OCoLC)1040623005
|
| 830 |
|
0 |
|a Micro & nano technologies.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128144701
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a 2.1.2. Other Cancers2.2. Regulation of Tumor Cell Growth and Migration Ability; 2.2.1. RPN2-Mediated N-Linked Glycosylation of CD63; 2.2.2. RPN2-Mediated N-Linked Glycosylation of Epidermal Growth Factor Receptor; 2.3. Roles of RPN2 in CSCs; 2.3.1. CSCs; 2.3.2. Breast CSCs; 2.3.3. EMT Regulators; 2.3.4. The Role of p53 in the Regulation of CSC Properties; 2.3.5. RPN2 Regulates Breast CSC Properties by Inactivating GSK-3β; 2.3.6. Clinical Significance of RPN2 in Breast Cancer; 3. Preclinical Development of RPN2-siRNA for Breast Cancer Patients; 3.1. Carrier for RPN2-siRNA Delivery
|
